Table 1 Demographic and clinical characteristics of the patients.

From: Correlation between paravertebral spread of injectate and clinical efficacy in lumbar transforaminal block

 

All patients (n = 54)

Responder (n = 26)

Non-responder (n = 28)

P value

Age, year

68.4 (9.4)

70.3 (6.8)

66.7 (11.1)

0.298

Sex, M/F

19/35

10/16

9/19

0.431

Diagnosis

   

0.024

 Spinal stenosis

48 (88.9%)

26 (100.0%)

22 (78.6%)

 

 HNP

6 (11.1%)

0 (0.0%)

6 (21.4%)

 

Duration of pain, months

   

0.857

  < 3

6 (11.1%)

3 (11.5%)

3 (10.7%)

 

 3–12

19 (35.2%)

8 (30.8%)

11 (39.3%)

 

  > 12

29 (53.7%)

15 (57.7%)

14 (50.0%)

 

Lesion level

   

0.879

 L2–3

1 (1.9%)

1 (3.8%)

0 (0.0%)

 

 L3–4

16 (29.6%)

8 (30.8%)

8 (28.6%)

 

 L4–5

37 (68.5%)

17 (65.4%)

20 (71.4%)

 

Lesion severity

   

0.586

 Mild

0 (0.0%)

0 (0.0%)

0 (0.0%)

 

 Moderate

27 (50.0%)

12 (46.2%)

15 (53.6%)

 

 Severe

27 (50.0%)

14 (53.8%)

13 (46.4%)

 
  1. All data are presented as mean (SD) or numbers (percentages) of patients. HNP, herniated nucleus pulposus; Responder, patients who showed a reduction of ≥ 50% on the numeric rate scale for pain at 30 min after the block; Non-responder, patients who showed a reduction of less than 50%.
Back to article page